GSTP1 and triple-negative breast carcinoma: Hence, repurposing these potent inhibitors to cancers that overexpress GST P1-1, such as the triple-negative breast cancer studied here (MDA-MB-231), and potentially other cancers, could lead to promising clinical outcomes.